Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease
Public ClinicalTrials.gov record NCT03357471. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-Label Study to Evaluate the Safe and Effective Use of an Electro-Mechanical Injection Device (E-Device) for the Subcutaneous Self-Injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease
Study identification
- NCT ID
- NCT03357471
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- UCB Biopharma S.P.R.L.
- Industry
- Enrollment
- 70 participants
Conditions and interventions
Conditions
Interventions
- e-Device Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2, 2017
- Primary completion
- Jul 1, 2018
- Completion
- Jul 1, 2018
- Last update posted
- Oct 24, 2019
2017 – 2018
United States locations
- U.S. sites
- 22
- U.S. states
- 12
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ra0098 116 | Mesa | Arizona | 85202 | — |
| Ra0098 107 | Mesa | Arizona | 85306 | — |
| Ra0098 135 | Phoenix | Arizona | 85037 | — |
| Ra0098 119 | Tucson | Arizona | 85704 | — |
| Ra0098 101 | Covina | California | 91722 | — |
| Ra0098 131 | Clermont | Florida | 34711 | — |
| Ra0098 132 | Coral Springs | Florida | 33071 | — |
| Ra0098 127 | Gainesville | Georgia | 30501 | — |
| Ra0098 122 | Clive | Iowa | 50265 | — |
| Ra0098 105 | St Louis | Missouri | 63110 | — |
| Ra0098 104 | St Louis | Missouri | 63128 | — |
| Ra0098 103 | Dover | New Jersey | 07801 | — |
| Ra0098 117 | Great Neck | New York | 11021 | — |
| Ra0098 113 | Myrtle Beach | South Carolina | 29572 | — |
| Ra0098 126 | Hixson | Tennessee | 37343 | — |
| Ra0098 111 | Austin | Texas | 78731 | — |
| Ra0098 123 | Austin | Texas | 78745 | — |
| Ra0098 102 | Austin | Texas | 78758 | — |
| Ra0098 128 | Corpus Christi | Texas | 78404 | — |
| Ra0098 106 | Nassau Bay | Texas | 77058 | — |
| Ra0098 114 | San Antonio | Texas | 78229 | — |
| Ra0098 133 | Richland | Washington | 99352 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03357471, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 24, 2019 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03357471 live on ClinicalTrials.gov.